Revolution Medicines (RVMD) Non-Current Deffered Revenue (2019 - 2022)
Revolution Medicines (RVMD) posted quarterly Non-Current Deffered Revenue of $5.4 million for Q3 2022, down 44.02% year-over-year from $9.7 million in Q3 2021, and up 41.2% quarter-over-quarter from $3.8 million in Q2 2022.
Revolution Medicines (RVMD) Non-Current Deffered Revenue (2019 - 2022) Analysis & Trends
Revolution Medicines' Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $5.4 million for Q3 2022.
- In Q3 2022, Non-Current Deffered Revenue fell 44.02% year-over-year to $5.4 million; the TTM figure through Sep 2022 stood at $5.4 million (down 44.02% YoY), while the FY2021 annual figure was $6.6 million, down 22.5% from the prior year.
- Non-Current Deffered Revenue for Q3 2022 stood at $5.4 million, up from $3.8 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $12.4 million in Q1 2020, with the low at $1.7 million in Q4 2019.
- The 4-year median for Non-Current Deffered Revenue is $7.9 million (2021), against an average of $7.6 million.
- The sharpest annual moves came in 2020 and 2022: Non-Current Deffered Revenue jumped 387.13% in 2020, then tumbled 49.65% in 2022.
- Revolution Medicines' Non-Current Deffered Revenue stood at $1.7 million in 2019, then surged by 387.13% to $8.5 million in 2020, then fell by 22.5% to $6.6 million in 2021, then fell by 17.57% to $5.4 million in 2022.
- Business Quant data shows RVMD's Non-Current Deffered Revenue at $5.4 million in Q3 2022, $3.8 million in Q2 2022, and $5.7 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 5.42 Mn |
| Jun 30, 2022 | 3.84 Mn |
| Mar 31, 2022 | 5.66 Mn |
| Dec 31, 2021 | 6.57 Mn |
| Sep 30, 2021 | 9.68 Mn |
| Jun 30, 2021 | 7.62 Mn |
| Mar 31, 2021 | 8.14 Mn |
| Dec 31, 2020 | 8.48 Mn |
| Sep 30, 2020 | 9.77 Mn |
| Jun 30, 2020 | 11.61 Mn |
| Mar 31, 2020 | 12.42 Mn |
| Dec 31, 2019 | 1.74 Mn |